海外の治験の状況「COVID-19」での検索結果
94件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A research study to compare the combined treatment of osimertinib and bevacizumab with osimertinib treatment alone in patients with lung cancer that has progressed or spread to other parts of the body (metastatic) and with confirmed specific gene mutations (changes) in the epithelial growth factor receptor (EGFR)
- Patients with locally advanced or metastatic (stage IIIb-IVb) EGFRm (exon 19 deletion or exon 21 L858R) NSCLC with T790M resistance mutation at progression on prior EGFR TKI therapy MedDRA version: 19.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10059515 Term: Non-small cell lung cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Ireland, Korea, Republic of, Netherlands, Singapore, Spain, Switzerland
- 2017-03-31
Authorised
- A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in patients with Non–Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor–Activating Mutations
- Male or female individuals, aged 18 years or older who have Stage IIIB/IV or recurrent NSCLC. Subjects must have tumors that are positive for EGFR-activating mutation, namely, exon 19 deletions, exon 21 L858R mutations, or point mutations at position 719. Enrolled subjects must have a life expectancy of at least 12 weeks and have adequate liver, kidney, and bone marrow function. MedDRA version: 18.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.0 Level: PT Classification code 10029515 Term: Non-small cell lung cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, European Union, Hong Kong, Israel, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States
- 2015-09-25
Not Recruiting
- The effect of cognitive-behavioral intervention on the burden and quality of life in drug dependence caregivers referred to the Shahid Modarres Hospital in 2016
- Drug dependence. Mental and Behavioral Disorders due to use of alcohol,opioids,cannabis;sedatives, hypnotics, anxiolytics,cocaine,other stimulants, including caffeine,hallucinogens,nicotine,inhalants and other psychoactive substances and multiple drug use;F10-19;Mental and Behavioral Disorders due to use of alcohol,opioids,cannabis;sedatives, hypnotics, anxiolytics,cocaine,other stimulants, including caffeine,hallucinogens,nicotine,inhalants and other psychoactive substances and multiple drug use
- Iran (Islamic Republic of)
- 2017-02-11
Not Recruiting
- Suicide prevention program at Khorram Abad, the capital of Lorestan province, Iran
- Condition 1: suicide. Condition 2: suicide. Condition 3: suicide. Condition 4: suicide. Condition 5: suicide. Condition 6: suicide. Condition 7: suicide. Condition 8: suicide. Condition 9: suicide. Condition 10: suicide. Condition 11: suicide. Condition 12: suicide. Condition 13: suicide. Condition 14: suicide. Condition 15: suicide. Condition 16: suicide. Condition 17: suicide. Condition 18: suicide. Condition 19: suicide. Condition 20: suicide. Condition 21: suicide. Condition 22: suicide. Condition 23: suicide. Condition 24: suicide. Condition 25: suicide. Condition 26: suicide. Condition 27: major depression. Condition 28: major depression. Condition 29: major depression. Condition 30: major depression. ntentional self-poisoning by and exposure to nonopioid analgesics, antipyretics and antirheumatics Intentional self-poisoning by and exposure to antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified ntentional self-poisoning by and exposure to other drugs acting on the autonomic nervous system ntentional self-poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified Intentional self-poisoning by and exposure to other and unspecified drugs, medicaments and biological substances Intentional self-poisoning by and exposure to alcohol Intentional self-poisoning by and exposure to alcohol ntentional self-poisoning by and exposure to organic solvents and halogenated hydrocarbon ntentional self-poisoning by and exposure to other gases and vapours Intentional self-poisoning by and exposure to pesticides Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances Intentional self-harm by hanging, strangulation and suffocation Intentional self-harm by drowning and submersion ntentional self-harm by handgun discharge Intentional self-harm by rifle, shotgun and larger firearm discharge
- Iran (Islamic Republic of)
- 2010-09-23
